Zejing pharmaceutical: an advance loss of 372 million yuan to 455 million yuan in 2021

China's First Oral COVID-19 Antiviral Medicine in Dispute

An obscure Chinese company called Genuine Biotech(Chinese: 真实生物) was suddenly put under the spotlight on July 25 when the Chinese authority announced the conditional approval of the company's application for adding the treatment of COVID-19 as a new indication of Azvudine under the special review and approval procedures for drug registration.

Unpacking China | Key Chinese Firms to Watch This Week （20/09/2026-26/09/2026）

Amid fast-paced changes that fill the business community with excitement, angst and trepidation, EqualOcean will publish a series of roundup articles to document the major events related to Chinese companies going global every week.

Beyond the Car: China’s Next Wave of Intelligent Hardware

The next chapter for intelligent vehicles is unfolding both inside and beyond the car.

Moonshot AI’s Kimi K3 Joins Amazon Bedrock as Overseas Revenue-Sharing Model Takes Shape

Amazon Web Services announced on September 18 that Kimi K3, developed by China’s Moonshot AI（月之暗面）, is available on Amazon Bedrock, expanding the model’s access to enterprise customers through AWS’s managed AI platform. On September 21, National Business Daily reported that Moonshot had confirmed an overseas cloud revenue-sharing arrangement, adding a commercial dimension to the launch. The financial terms remain undisclosed.

Junshi Biosciences Receives NMPA Approval of sNDA for Toripalimab

The study data showed that compared to chemotherapy alone, toripalimab in combination with chemotherapy in the first-line treatment of patients with advanced NSCLC without EGFR/ALK mutations could significantly improve the PFS and the OS of patients with a manageable safety profile regardless of PD-L1 expression status.